How were Imago BioSciences' earnings last quarter?

Imago BioSciences, Inc. (NASDAQ:IMGO) posted its earnings results on Wednesday, November, 10th. The company reported ($0.44) earnings per share for the quarter, missing analysts' consensus estimates of ($0.34) by $0.10.

When did Imago BioSciences IPO?

Imago BioSciences (IMGO) raised $105 million in an initial public offering (IPO) on Friday, July 16th 2021. The company issued 7,000,000 shares at a price of $14.00-$16.00 per share.

NASDAQ:IMGO

Imago BioSciences (IMGO) Stock Price, News & Analysis

→ New crypto project uncovers 2,050% in 65 days (From InvestorPlace) (Ad)

Free IMGO Stock Alerts

Notice: This company has been marked as potentially delisted and may not be actively trading.

Compare

Today's Range: $36.01
▼
$36.01
50-Day Range: $35.78
▼
$36.01
52-Week Range: $11.56
▼
$36.09

Volume: N/A
Average Volume: 171,367 shs
Market Capitalization: $1.22 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Stock Analysis

Get Imago BioSciences alerts:

Ad InvestorPlace

New crypto project uncovers 2,050% in 65 days

During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.

Just click here to sign up and be among the first to get it.

About Imago BioSciences Stock (NASDAQ:IMGO)

Imago BioSciences, Inc., a clinical stage biopharmaceutical company, discovers and develops small molecule product candidates that target lysine-specific demethylase 1(LSD1), an enzyme that used in the production of blood cells in the bone marrow. Its lead product candidate is bomedemstat, which is in Phase II clinical trials for the treatment of myeloproliferative neoplasms chronic cancers of the bone marrow, such as myelofibrosis, essential thrombocythemia, and polycythemia vera. The company was incorporated in 2012 and is headquartered in South San Francisco, California.

Ad InvestorPlace

New crypto project uncovers 2,050% in 65 days

During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.

Just click here to sign up and be among the first to get it.

IMGO Stock News Headlines

April 13, 2024 | msn.com

Imago Theatre aims to find out if time-traveling Neanderthals have answers to climate change

April 2, 2024 | seekingalpha.com

Merck: Better Times Ahead On Approvals And Outlook

April 19, 2024 | InvestorPlace (Ad)

New crypto project uncovers 2,050% in 65 days

During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.

February 23, 2024 | benzinga.com

Clarus Lifesciences III, L.P.'s Net Worth

December 21, 2023 | morningstar.com

Anixa Biosciences Inc ANIX

February 23, 2023 | benzinga.com

Harmony Biosciences shares are trading lower after the company reported Q4 financial results.

January 11, 2023 | markets.businessinsider.com

Merck To Complete Acquisition Of Imago

January 11, 2023 | finance.yahoo.com

Merck Completes Tender Offer to Acquire Imago BioSciences, Inc.

April 19, 2024 | InvestorPlace (Ad)

New crypto project uncovers 2,050% in 65 days

During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.

January 4, 2023 | msn.com

Looking Into Imago BioSciences's Recent Short Interest

December 30, 2022 | seekingalpha.com

Merck is best performing large U.S. pharma of 2022

December 20, 2022 | finance.yahoo.com

Imago BioSciences Announces First Participant Dosed in Investigator-Sponsored Phase 2 Study of Bomedemstat in Combination with Ruxolitinib in Myelofibrosis

December 13, 2022 | markets.businessinsider.com

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ELVT, IMGO, GRAY, USER

December 12, 2022 | finance.yahoo.com

Imago BioSciences Presents Positive Data from Ongoing Phase 2 Study of Bomedemstat in Essential Thrombocythemia at ASH 2022

December 12, 2022 | finance.yahoo.com

Imago BioSciences Presents Positive Data from Ongoing Phase 2 Study of Bomedemstat in Advanced Myelofibrosis at ASH 2022

December 12, 2022 | markets.businessinsider.com

Merck Commences Tender Offer To Acquire Imago BioSciences

December 9, 2022 | msn.com

How Is The Market Feeling About Imago BioSciences?

November 30, 2022 | seekingalpha.com

Imago BioSciences: The Bone Marrow Cancer Researcher Reaches Milestone

November 30, 2022 | finance.yahoo.com

Imago BioSciences Announces First Participant Dosed in Investigator-Sponsored Phase 1 Study of Bomedemstat in Combination with Venetoclax in Relapsed/Refractory Acute Myeloid Leukemia

November 29, 2022 | finance.yahoo.com

Horizon Therapeutics Fields Takeover Interest From Pharma Giants

November 29, 2022 | benzinga.com

SHAREHOLDER ALERT: The M&A Class Action Firm Announces the Investigation of Imago BioSciences, Inc. - IMGO

November 28, 2022 | markets.businessinsider.com

Analyst Ratings for Imago BioSciences

November 25, 2022 | finance.yahoo.com

Pharma Stock Roundup: MRK to Buy IMGO, ABBV's Skyrizi Gets EU Nod for New Indication

November 24, 2022 | 247wallst.com

Imago Bio Shares Soar on Agreement to Selll to Merck for $1.35 Billion Cash

November 22, 2022 | markets.businessinsider.com

Expert Ratings for Imago BioSciences

November 22, 2022 | markets.businessinsider.com

What 5 Analyst Ratings Have To Say About Imago BioSciences

November 22, 2022 | finance.yahoo.com

Imago (IMGO) Shares Surge 104% on Buyout Offer From Merck

See More Headlines

Receive IMGO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Imago BioSciences and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/10/2021
Today: 4/18/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:IMGO
CUSIP: N/A
CIK: 1623715
Web: www.imagobio.com
Phone: 415-529-5055
Fax: N/A
Employees: 27
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): ($1.84)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-42,310,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -31.85%
Return on Assets: -30.07%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 13.15
Quick Ratio: 13.16

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $6.40 per share
Price / Book: 5.63

Miscellaneous

Outstanding Shares: 33,822,000
Free Float: 28,783,000
Market Cap: $1.22 billion
Optionable: Not Optionable
Beta: 2.82

Metaverse Stocks And Why You Can't Ignore Them

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Key Executives

Dr. Hugh Young Rienhoff Jr. (Age 70)
M.D., CEO & Director
Comp: $701.78k
Ms. Laura G. Eichorn (Age 51)
Chief Financial Officer
Comp: $456.06k
Mr. Michael H. Arenberg J.D. (Age 53)
M.B.A., Chief Operating & Bus. Officer
Ms. Hsiangyi Chiang (Age 56)
Sr. VP of Fin. & Principal Accounting Officer
Dr. Amy E. Tapper Ph.D. (Age 52)
Chief of Technical Operations
Ms. Jennifer Peppe (Age 53)
Global Head of Clinical Operations

Key Competitors

View All Competitors

IMGO Stock Analysis - Frequently Asked Questions

How were Imago BioSciences' earnings last quarter?: Imago BioSciences, Inc. (NASDAQ:IMGO) posted its earnings results on Wednesday, November, 10th. The company reported ($0.44) earnings per share for the quarter, missing analysts' consensus estimates of ($0.34) by $0.10.
When did Imago BioSciences IPO?: Imago BioSciences (IMGO) raised $105 million in an initial public offering (IPO) on Friday, July 16th 2021. The company issued 7,000,000 shares at a price of $14.00-$16.00 per share.

This page (NASDAQ:IMGO) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Imago BioSciences (IMGO) Stock Price, News & Analysis

About Imago BioSciences Stock (NASDAQ:IMGO)

IMGO Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

IMGO Stock Analysis - Frequently Asked Questions

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info